YICHANG HEC CHANGJIANG PHARMACEUTICAL CO., LTD.

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

1558

CNE1000023R6

Pharmaceuticals

Delayed Hong Kong S.E. Other stock markets 08:08:50 29/05/2024 am IST			5-day change	1st Jan Change
9.82 ^HKD	-1.11%		-4.63%	+4.11%

08/05	Yichang HEC Still Negotiating Merger Deal with Sunshine Lake Pharma	MT
09/04	Yichang Hec Changjiang Pharmaceutical Updates on Possible Merger with Sunshine Lake Pharma	MT

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Appoints Li Xuechen as an Independent Non-Executive Director

September 25, 2020 at 04:21 pm IST

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. announced that at its EGM held on 25 September 2020, approved the appointment of Mr. Li Xuechen as an independent non-executive director of the company with effect from 25 September 2020.

Latest news about YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

Yichang HEC Still Negotiating Merger Deal with Sunshine Lake Pharma	08/05	MT
Yichang Hec Changjiang Pharmaceutical Updates on Possible Merger with Sunshine Lake Pharma	09/04	MT
Yichang Hec Changjiang Pharmaceutical's Net Profit Surges in 2023 as Revenue Jumps	01/04	MT
YiChang HEC ChangJiang Pharmaceutical's Profit Surges in 2023	29/03	MT
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
Yichang Hec Changjiang Pharmaceutical Expects Up to 2,627% Profit Surge in 2023	13/03	MT
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Provides Group Earnings Guidance for the Year Ended 31 December 2023	12/03	CI
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. and Sunshine Lake Pharma Enter into Drug R&D Pipeline Cooperation Project Framework Agreement	29/11	CI
HEC ChangJiang Pharmaceutical Increases Transaction Limits Under 2 Contracts	08/11	MT
HEC ChangJiang Pharmaceutical's Insulin Injection Cleared for Market Launch in China	26/23/26	MT
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Receives Approval for Mixed Protamine Human Insulin Injection from the China National Medical Products Administration	25/23/25	CI
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.Approves Announces Executive Changes	08/23/08	CI
HEC ChangJiang Pharmaceutical Returns to Profit on Surge in Anti-Viral Drug Sales	01/23/01	MT
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	31/23/31	CI
China Greenlights New Drug Application for HEC ChangJiang Pharmaceutical's Hepatitis C Drug	16/23/16	MT
National Medical Products Administration of the People's Republic of China Accepts the Application for Launching Yiqibuvir Tablets	15/23/15	CI
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Announces Resignation of Chen Yangui as Executive Director	14/23/14	CI
HEC ChangJiang Pharmaceutical Forecasts Surge in H1 Profit; Shares Rise 5%	27/23/27	MT
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Six Months Ended June 30, 2023	26/23/26	CI
HEC ChangJiang Pharma Repurchases $400 Million Convertible Bonds Issued to Blackstone	06/23/06	MT
HEC Chang Jiang Pharma Completes Equity Transfer in Unit	28/23/28	MT
GUO Meilan and ZHANG Yushuai completed the acquisition of 9.9134% stake in Sunshine Lake Pharma Co., Ltd. from YiChang HEC ChangJiang Pharmaceutical Co., Ltd..	27/23/27	CI
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	24/23/24	CI
YiChang HEC ChangJiang Pharma to Return to Profitability	20/23/20	MT
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Provides Unaudited Earnings Guidance for the Year Ended 31 December 2022	17/23/17	CI

Chart YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

Duration

Period

Chart YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

More charts

Company Profile

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is a China-based company principally engaged in the manufacture and sales of pharmaceutical products. The Company is also engaged in the research and development, marketing and distribution of pharmaceuticals. The products of the Company include anti-viral drugs, endocrine and metabolic drugs and cardiovascular drugs. Its main products include Kewei, Ertongshu, Oumeining, Xinhaining and Xining.

Sector

Pharmaceuticals

Calendar

23/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

9.211 CNY

Average target price

14.33 CNY

Spread / Average Target

+55.60%

Consensus

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
YICHANG HEC CHANGJIANG PHARMACEUTICAL CO., LTD.	+4.11%	1.14B
ELI LILLY AND COMPANY	+38.59%	727B
JOHNSON & JOHNSON	-7.89%	354B
MERCK & CO., INC.	+15.66%	328B
ABBVIE INC.	+0.24%	277B
ASTRAZENECA PLC	+13.47%	243B
NOVARTIS AG	+7.35%	205B
ROCHE HOLDING AG	-6.42%	203B
AMGEN INC.	+4.23%	164B
PFIZER, INC.	-1.70%	164B

Other Pharmaceuticals